US4812448A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
Assignee: Individual
•
Filing: 1986-10-14
•
Granted: 1989-03-14
•
Expires: 2006-10-14
Abstract
Abstract A novel pharmacologic therapy for treatment of idiopathic primary open angle glaucoma, drug-induced glaucoma and elevated intraocular pressure is disclosed. The pharmacologic therapy consists of a novel composition comprised of 17-alpha-methyl-testosterone and a physiologically tolerable carrier. In accordance with a method aspect of this invention, the active ingredient is administered to the eye of a warm blooded animal in such a manner as to maintain physiologic or normal intraocular pressure, or to return elevated intraocular pressure to normal levels. The method aspect of this invention may also be employed to ameliorate drug induced elevated intraocular pressure.
Inventors
- 👤 Paul A. Knepper
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 16:44
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/58; A61K31/565
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
46 words
A method for reducing elevated intraocular pressure in an eye of a warm blooded animal which comprises contacting the affected eye with an intraocular pressure reducing amount of 17-alpha-methyl-testosterone 1 to about 6 times per day for a time period of at least about three days.
Claim 2
Independent Claim
46 words
A method for reducing elevated intraocular pressure in an eye of a warm blooded animal which comprises contacting the affected eye with an intraocular pressure reducing amount of 17-alpha-methyl-testosterone 1 to about 6 times per day for a time period of at least about three days.
Claim 3
Dependent Claim
37 words
The method in accordance with claim 1 wherein the contacting is effected by repeated administration of 17-alpha-methyl-testosterone to the eye at predetermined intervals and in a unit dose of about 0.001 to about 10 milligrams per administration.
Claim 4
Dependent Claim
22 words
The method in accordance with claim 2 wherein the unit dose is in a range of about 0.004 to about 4 milligrams.
Claim 5
Dependent Claim
40 words
The method in accordance with claim 1 wherein the contacting is effected by injecting an effective amount of 17-alpha-methyl-testosterone in a physiologically tolerable vehicle into a body structure of said animal adjacent to the ocular filter mechanism of said animal.
Claim 6
Dependent Claim
19 words
The method in accordance with claim 1 wherein the 17-alpha-methyl-testosterone is injected beneath the Tenon's capsule of the eye.
Claim 7
Independent Claim
73 words
A method of reducing elevated intraocular pressure in an eye of a warm blooded animal which elevated intraocular pressure is caused by administration of an intraocular pressure elevating composition to that animal which comprises contacting the eye with an intraocular pressure reducing amount of 17-alpha-methyl-testosterone substantially concurrently with the administration of said intraocular pressure elevating composition and continuing said contacting until said intraocular pressure elevating composition is no longer administered to the eye.
Claim 8
Independent Claim
73 words
A method of reducing elevated intraocular pressure in an eye of a warm blooded animal which elevated intraocular pressure is caused by administration of an intraocular pressure elevating composition to that animal which comprises contacting the eye with an intraocular pressure reducing amount of 17-alpha-methyl-testosterone substantially concurrently with the administration of said intraocular pressure elevating composition and continuing said contacting until said intraocular pressure elevating composition is no longer administered to the eye.
Claim 9
Dependent Claim
37 words
The method in accordance with claim 6 wherein the contacting is effected by repeated administration of 17-alpha-methyl-testosterone to the eye at predetermined intervals and in a unit dose of about 0.001 to about 10 milligrams per administration.
Claim 10
Dependent Claim
38 words
The method in accordance with claim 6 wherein the contacting is effected by repeated administration of the 17-alpha-methyl-testosterone to the eye at predetermined intervals and in a unit dose of about 0.004 to about 4 milligrams per administration.
Claim 11
Dependent Claim
23 words
The method in accordance with claim 6 wherein the contacting is done by injection of 17-alpha-methyl-testosterone beneath the Tenon's capsule of the eye.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-03-13 | 1992-09-12 | 1993-03-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-03-13 | 1996-09-12 | 1997-03-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-03-13 | 2000-09-12 | 2001-03-14 | $7700.00 | Window Closed / Lapsed |